Menu Search
Equities

Observe Medical ASA

OM5A:FRA

Observe Medical ASA

Actions
  • Price (EUR)0.0276
  • Today's Change0.00 / 0.00%
  • Shares traded1.00k
  • 1 Year change+14.95%
  • Beta--
Data delayed at least 15 minutes, as of Nov 21 2024 14:29 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in NOKIncome statement in NOKView more

Year on year Observe Medical ASA had net income fall 18.82% from a loss of 50.80m to a larger loss of 60.36m despite revenues that grew 43.14% from 19.52m to 27.94m over the same period.
Gross margin--
Net profit margin--
Operating margin--
Return on assets--
Return on equity--
Return on investment--
More ▼

Cash flow in NOKView more

In 2023, Observe Medical ASA did not generate a significant amount of cash. Cash Flow from Financing totalled 31.74m or 113.59% of revenues. In addition the company used 24.46m for operations while cash used for investing totalled 7.63m.
Cash flow per share--
Price/Cash flow per share--
Book value per share0.5635
Tangible book value per share-0.579
More ▼

Balance sheet in NOKView more

Observe Medical ASA has a Debt to Total Capital ratio of 34.25%, a higher figure than the previous year's 1.17%.
Current ratio0.2527
Quick ratio0.193
Total debt/total equity0.5209
Total debt/total capital0.3425
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.